

## In this issue

Luciana M. Herda, Ester Polo,  
Philip M. Kelly, Louise Rocks, Diána  
Hudecz and Kenneth A. Dawson


### Designing the future of nanomedicine: current barriers to targeted brain therapeutics

DOI 10.1515/ejnm-2014-0022

Eur. J. Nanomed. 2014; 6(3): 127–139

**Review article:** The challenges facing nanosystem designs for crossing the blood-brain barrier through receptor-mediated transcytosis range from affinity modulation of targeting moieties for selectivity and efficacy, to behaviour in biological media.

**Keywords:** apoE; blood-brain barrier; drug targeting; nanoparticles; receptor-mediated transcytosis; transferrin.




Cinzia Casella, Martina Tuttolo-  
mondo, Poul Flemming Høilund-  
Carlsen and Jan Mollenhauer  
**Natural pattern recognition  
mechanisms at epithelial barriers  
and potential use in nanomedicine**

DOI 10.1515/ejnm-2014-0020

Eur. J. Nanomed. 2014; 6(3): 141–155

**Review article:** Molecular pattern recognition is a generic mechanism in defense and extracellular matrix interactions. Understanding its molecular basis may substantially assist rational design of novel nanomedical principles for drug delivery.

**Keywords:** DMBT1; drug delivery; epithelial barrier; innate immunity; pattern recognition.




Xabi Murgia, Cristiane de Souza  
Carvalho and Claus-Michael Lehr  
**Overcoming the pulmonary barrier:  
new insights to improve the  
efficiency of inhaled therapeutics**

DOI 10.1515/ejnm-2014-0019

Eur. J. Nanomed. 2014; 6(3): 157–169

**Review article:** After successful lung deposition therapeutic nanoparticles must overcome the pulmonary barriers in order to carry out their therapeutic effect. In the conducting airways the mucus layer (8  $\mu\text{m}$  thick) on top of the epithelial cells (58  $\mu\text{m}$  thick) creates a heterogeneous mesh that poses a significant barrier to inhaled nanoparticles. In the deep lung, the pulmonary surfactant (0.07  $\mu\text{m}$  thick), the macrophages, and the alveolar epithelium (0.1–0.2  $\mu\text{m}$  thick) are the main barriers for therapeutic nanoparticles.

**Keywords:** mucus; nanoparticles; pulmonary barriers; respiratory epithelium; surfactant.



Maria Rita Fabbri, Tracey Duff,  
Jo Oliver and Colin Wilde


**Advanced in vitro systems for  
efficacy and toxicity testing in  
nanomedicine**

DOI 10.1515/ejnm-2014-0018

Eur. J. Nanomed. 2014; 6(3): 171–183

**Review article:** Novel cell-based models incorporating physiologically-relevant cells cultured in tissue-reflective 3D environments deliver the means for predictive preclinical testing of nano-therapies and the prospect of accelerating the development of nanomedicines.

**Keywords:** cell-based systems; commercial platforms; nanosafety.



Diána Hudecz, Louise Rocks, Laurence W. Fitzpatrick, Luciana-Maria Herda and Kenneth A. Dawson  
**Reproducibility in biological models of the blood-brain barrier**

DOI 10.1515/ejnm-2014-0021

Eur. J. Nanomed. 2014; 6(3): 185–193

**Mini Review:** Alternative approaches to traditional in vitro blood-brain barrier models may be required to improve experimental reproducibility.

**Keywords:** blood-brain barrier; in vitro; live cell imaging; nanoparticle; reproducibility; transcytosis.

